Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Mark H. O'Hara"'
Autor:
Jacob E. Till, Lee McDaniel, Changgee Chang, Qi Long, Shannon M. Pfeiffer, Jaclyn P. Lyman, Lacey J. Padrón, Deena M. Maurer, Jia Xin Yu, Christine N. Spencer, Pier Federico Gherardini, Diane M. Da Silva, Theresa M. LaVallee, Charles Abbott, Richard O. Chen, Sean M. Boyle, Neha Bhagwat, Samuele Cannas, Hersh Sagreiya, Wenrui Li, Stephanie S. Yee, Aseel Abdalla, Zhuoyang Wang, Melinda Yin, Dominique Ballinger, Paul Wissel, Jennifer Eads, Thomas Karasic, Charles Schneider, Peter O’Dwyer, Ursina Teitelbaum, Kim A. Reiss, Osama E. Rahma, George A. Fisher, Andrew H. Ko, Zev A. Wainberg, Robert A. Wolff, Eileen M. O’Reilly, Mark H. O’Hara, Christopher R. Cabanski, Robert H. Vonderheide, Erica L. Carpenter
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract While high circulating tumor DNA (ctDNA) levels are associated with poor survival for multiple cancers, variant-specific differences in the association of ctDNA levels and survival have not been examined. Here we investigate KRAS ctDNA (ctKR
Externí odkaz:
https://doaj.org/article/4f9cd688d606493b979047418e6f71a0
Autor:
Adham S. Bear, Tatiana Blanchard, Joseph Cesare, Michael J. Ford, Lee P. Richman, Chong Xu, Miren L. Baroja, Sarah McCuaig, Christina Costeas, Khatuna Gabunia, John Scholler, Avery D. Posey, Mark H. O’Hara, Anze Smole, Daniel J. Powell, Benjamin A. Garcia, Robert H. Vonderheide, Gerald P. Linette, Beatriz M. Carreno
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
KRAS is commonly mutated at codon 12 in several cancer types, offering a unique opportunity for the development of neoantigen-targeted immunotherapy. Here the authors present a pipeline for the prediction, identification and validation of HLA class-I
Externí odkaz:
https://doaj.org/article/5c32458bd77b40989a4cd89c57021223
Autor:
William J. Chapin, Jacob E. Till, Wei-Ting Hwang, Jennifer R. Eads, Thomas B. Karasic, Peter J. O'Dwyer, Charles J. Schneider, Ursina R. Teitelbaum, Janae Romeo, Taylor A. Black, Theresa E. Christensen, Colleen Redlinger Tabery, Amanda Anderson, Megan Slade, Michael LaRiviere, Stephanie S. Yee, Kim A. Reiss, Mark H. O'Hara, Erica L. Carpenter
Publikováno v:
JCO precision oncology. 6
PURPOSE Pancreatic ductal adenocarcinoma (PDAC) is associated with a poor prognosis. Multianalyte signatures, including liquid biopsy and traditional clinical variables, have shown promise for improving prognostication in other solid tumors but have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69b5c3a9a69c1348cb58b0dfe0498373
https://pubmed.ncbi.nlm.nih.gov/35939771
https://pubmed.ncbi.nlm.nih.gov/35939771
Autor:
Lacey J. Padrón, Deena M. Maurer, Mark H. O’Hara, Eileen M. O’Reilly, Robert A. Wolff, Zev A. Wainberg, Andrew H. Ko, George Fisher, Osama Rahma, Jaclyn P. Lyman, Christopher R. Cabanski, Jia Xin Yu, Shannon M. Pfeiffer, Marko Spasic, Jingying Xu, Pier Federico Gherardini, Joyson Karakunnel, Rosemarie Mick, Cécile Alanio, Katelyn T. Byrne, Travis J. Hollmann, Jonni S. Moore, Derek D. Jones, Marco Tognetti, Richard O. Chen, Xiaodong Yang, Lisa Salvador, E. John Wherry, Ute Dugan, Jill O’Donnell-Tormey, Lisa H. Butterfield, Vanessa M. Hubbard-Lucey, Ramy Ibrahim, Justin Fairchild, Samantha Bucktrout, Theresa M. LaVallee, Robert H. Vonderheide
Publikováno v:
Nature Medicine. 28:1167-1177
Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). We conducted a randomized phase 2 trial evaluating the efficacy of nivolum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c255f130b9f376c06edb269830b1d6b2
https://doi.org/10.1038/s41591-022-01829-9
https://doi.org/10.1038/s41591-022-01829-9
Publikováno v:
American Society of Clinical Oncology Educational Book.
Outcomes for patients with advanced pancreatic cancer have improved in the past 12 years, mainly because of progress made in systemic therapies. New treatment strategies for advanced pancreatic cancer include switch maintenance with cytotoxic therapi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5307c5c1c9012268107a0fede4ce7c52
https://doi.org/10.1200/edbk_397082
https://doi.org/10.1200/edbk_397082
Autor:
Erica L. Carpenter, David Issadore, Ben Z. Stanger, Bryson W. Katona, Charles M. Vollmer, Mark H. O'Hara, Andrew Adallah, Daniel Herman, Neha Bhagwat, Hanfei Shen, Andrew Lin, Kyle Tien, Taylor A. Black, Stephanie S. Yee, Theresa Christensen, Jacob E. Till, Jina Ko, Michael J. LaRiviere, Zijian Yang
Figure S1. Sample cohort of this study, which included 204 subjects in total. Workflow shows patient cohorts involved in each classification. * indicated 8 patients repeated in the discovery set and the training set. ** indicated 32 locally advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54dc6365a97a1024585caf83e8d7015e
https://doi.org/10.1158/1078-0432.22476264
https://doi.org/10.1158/1078-0432.22476264
Autor:
Zhuoyang Wang, Charu Aggarwal, Stephanie S. Yee, Aseel Abdalla, Jacob Till, Taylor A. Black, Robyn T. Sussman, Jacquelyn J. Roth, Kojo S.J. Elenitoba-Johnson, Erica L. Carpenter, Wei-Ting Hwang, Hareena Sangha, Caren Gentile, Jeffrey C. Thompson, Mark H. O'Hara
Publikováno v:
J Mol Diagn
Circulating cell-free DNA (ccfDNA) is used increasingly as a cancer biomarker for prognostication, as a correlate for tumor volume, or as input for downstream molecular analysis. Determining optimal blood processing and ccfDNA quantification are cruc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef407627d2b0842277092e087e0e4988
https://doi.org/10.1016/j.jmoldx.2021.08.007
https://doi.org/10.1016/j.jmoldx.2021.08.007
Autor:
Zain M. Hannan, Kim A. Reiss, Natallia Izgur, Ursina R. Teitelbaum, Susan M. Domchek, Robert H. Vonderheide, Charles Schneider, Thomas B. Karasic, Katherine L. Nathanson, Gregory L. Beatty, Rosemarie Mick, Rashmi Tondon, Stacy Cowden, Mark H. O'Hara, Janae Romeo, Traci Southwell, Max M. Wattenberg
Publikováno v:
Journal of Clinical Oncology. 39:2497-2505
PURPOSE Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved as maintenance therapy for patients with advanced pancreatic cancer (PC) and a germline BRCA1 or BRCA2 pathogenic variant (PV). This investigator-initiated, single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f04f815e04ccf12910bb0a391cc45f96
https://doi.org/10.1200/jco.21.00003
https://doi.org/10.1200/jco.21.00003
Autor:
P. J. O'Dwyer, Mark H. O'Hara, Shun Yu, Ofer Margalit, Kim A. Reiss, Ronac Mamtani, Bruce J. Giantonio, Einat Shacham Shmueli, Ben Boursi
Publikováno v:
Clinical Colorectal Cancer. 20:121-129
Introduction The use of total neoadjuvant therapy (TNT) for locally advanced rectal cancer has been increasing in recent years, but the long-term overall survival characteristics of this approach is currently unknown. Methods We performed a retrospec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::599ac12884613660c879ffb26a65d250
https://doi.org/10.1016/j.clcc.2021.01.001
https://doi.org/10.1016/j.clcc.2021.01.001
Publikováno v:
American Society of Clinical Oncology Educational Book. :57-65
Cancer immunotherapy tools include antibodies, vaccines, cytokines, oncolytic viruses, bispecific molecules, and cellular therapies. This review will focus on adoptive cellular therapy, which involves the isolation of a patient’s own immune cells f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d2ddd3bcd1d270fb99fe12fc91ab4fa
https://doi.org/10.1200/edbk_321115
https://doi.org/10.1200/edbk_321115